Description

Product Description

Envafolimab is a fully human monoclonal antibody that selectively binds to programmed cell death protein 1 (PD-1), an immune checkpoint receptor expressed on activated T cells. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, Envafolimab restores T-cell activation, promoting cytotoxic immune responses against tumor cells in preclinical models.

Structurally, Envafolimab is an IgG4 isotype antibody with engineered Fc region modifications to minimize effector function while maintaining target binding. Its high specificity and affinity allow precise modulation of PD-1 signaling, making it a valuable tool for mechanistic and translational oncology research.

In vitro studies demonstrate that Envafolimab enhances T-cell proliferation, cytokine secretion (including IFN-γ and IL-2), and cytotoxic activity in co-culture assays with tumor cells. In vivo xenograft models reveal its capacity to reduce tumor growth, increase tumor-infiltrating lymphocytes (TILs), and alter the tumor microenvironment favorably toward immune activation.

Preclinical applications of Envafolimab include:

• Immune checkpoint blockade studies: Evaluating T-cell activation and PD-1/PD-L1 pathway modulation.

• Tumor immunology assays: Assessing cytotoxicity, cytokine release, and TIL infiltration in murine and humanized models.

• Combination therapy research: Studying synergistic effects with chemotherapeutics, targeted therapies, or other immunotherapies.

• Resistance mechanism analysis: Investigating compensatory immunosuppressive pathways under PD-1 blockade.

Envafolimab is supplied as a highly pure (>99%) lyophilized protein, stable under recommended laboratory storage conditions. Its formulation ensures reproducibility across in vitro and in vivo experiments, providing researchers with consistent, high-quality material for immune-oncology studies.

Product Specifications

Mechanism of Action

Envafolimab functions as a PD-1 immune checkpoint inhibitor. Its primary mechanism involves binding to PD-1 on activated T cells, preventing interaction with PD-L1 and PD-L2 expressed on tumor or antigen-presenting cells. This blockade relieves T-cell suppression and enhances anti-tumor immune responses.

PD-1/PD-L1 Blockade

Envafolimab prevents PD-1-mediated inhibitory signaling, restoring T-cell receptor (TCR)-dependent activation. Preclinical studies show increased proliferation of CD8+ cytotoxic T lymphocytes and augmented cytokine secretion, critical for tumor cell lysis.

Tumor Microenvironment Modulation

By reactivating T cells, Envafolimab promotes infiltration of effector T cells into the tumor microenvironment and reduces immunosuppressive signaling. Researchers can study changes in TIL populations, tumor-associated macrophages, and other stromal interactions.

Combination and Translational Applications

Envafolimab is frequently used in combination studies with chemotherapeutic agents, targeted inhibitors, or other immune checkpoint modulators. These experiments allow investigation of synergistic effects, immune modulation dynamics, and resistance mechanisms in preclinical cancer models.

Side Effects

In laboratory preclinical studies, Envafolimab demonstrates predictable immune checkpoint blockade effects:

• Immune activation: Enhanced T-cell proliferation and cytokine secretion.

• Cytotoxicity modulation: Increased killing of target tumor cells in co-culture assays.

• Microenvironment alteration: Enhanced TIL infiltration, altered cytokine milieu.

• Dose-dependent effects: Observed changes are generally dependent on experimental concentration and exposure.

Laboratory Safety Guidelines:

• Wear appropriate personal protective equipment (PPE), including gloves, lab coat, and eye protection.

• Handle under a biosafety cabinet; avoid direct contact and inhalation.

• Store at 2–8 °C, protected from light and moisture.

• Dispose of all biological waste per institutional protocols.

Envafolimab is intended strictly for laboratory research use only.

Keywords

Envafolimab, PD-1 monoclonal antibody, immune checkpoint inhibitor, preclinical oncology research, T-cell activation studies, tumor immunology, laboratory biologics supplier, high-purity antibody

Shipping Guarantee

All Envafolimab shipments are handled using validated cold-chain logistics to maintain protein integrity. Each vial is sealed in moisture-proof containers with secondary protection. Continuous temperature monitoring ensures stability during transit. Express international couriers with full tracking and insurance are used, supporting global research shipments.

Trade Assurance

We guarantee Envafolimab authenticity with verified ≥99% purity and compliance with analytical standards such as SDS-PAGE and SEC-HPLC. Each batch is accompanied by a Certificate of Analysis (CoA). Any deviation from listed specifications qualifies for replacement or refund under our trade assurance policy.

Payment Support

Flexible international payment options include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and select cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are encrypted, verified, and protected by secure payment gateways to ensure confidentiality and fund security.

Disclaimer

All products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics. Researchers must comply with institutional biosafety and chemical safety guidelines. Information provided is solely for scientific reference.